 Dobutamine
"Dobutamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
| Descriptor ID |
D004280
|
| MeSH Number(s) |
D02.092.311.220 D02.092.471.683.410
|
| Concept/Terms |
Dobutamin-ratiopharm- Dobutamin-ratiopharm
- Dobutamin ratiopharm
- ratiopharm Brand of Dobutamine Hydrochloride
Dobutamine Tartrate- Dobutamine Tartrate
- Tartrate, Dobutamine
- Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
Dobutrex- Dobutrex
- Irisfarma Brand of Dobutamine Hydrochloride
- Lilly Brand of Dobutamine Hydrochloride
- Eli Lilly Brand of Dobutamine Hydrochloride
Oxiken- Oxiken
- Kendrick Brand of Dobutamine Hydrochloride
Posiject- Posiject
- Boehringer Ingelheim Brand of Dobutamine Hydrochloride
Dobucor- Dobucor
- Juste Brand of Dobutamine Hydrochloride
Dobuject- Dobuject
- Pisa Brand of Dobutamine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Dobutamine".
Below are MeSH descriptors whose meaning is more specific than "Dobutamine".
This graph shows the total number of publications written about "Dobutamine" by people in this website by year, and whether "Dobutamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 0 | 1 | 1 | | 1988 | 1 | 2 | 3 | | 1990 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 2 | 2 | | 1998 | 1 | 4 | 5 | | 1999 | 1 | 2 | 3 | | 2000 | 2 | 1 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 2 | 2 | 4 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dobutamine" by people in Profiles.
-
Fernandes GW, Ueta CB, Fonseca TL, Gouveia CH, Lancellotti CL, Brum PC, Christoffolete MA, Bianco AC, Ribeiro MO. Inactivation of the adrenergic receptor ß2 disrupts glucose homeostasis in mice. J Endocrinol. 2014 Jun; 221(3):381-90.
-
McNally EM. Can we do better than dobutamine? Circ Res. 2013 Aug 02; 113(4):355-7.
-
Bhave NM, Patel AR, Shah AP, Lang RM. Postextrasystolic potentiation in low-gradient, severe aortic stenosis: a poor man's stress echo? Echocardiography. 2013 Jul; 30(6):E148-51.
-
Piao L, Fang YH, Parikh KS, Ryan JJ, D'Souza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, Akhter SA, Archer SL. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation. 2012 Dec 11; 126(24):2859-69.
-
Ueta CB, Fernandes GW, Capelo LP, Fonseca TL, Maculan FD, Gouveia CH, Brum PC, Christoffolete MA, Aoki MS, Lancellotti CL, Kim B, Bianco AC, Ribeiro MO. ß(1) Adrenergic receptor is key to cold- and diet-induced thermogenesis in mice. J Endocrinol. 2012 Sep; 214(3):359-65.
-
Gayat E, Mor-Avi V, Weinert L, Yodwut C, Lang RM. Noninvasive quantification of left ventricular elastance and ventricular-arterial coupling using three-dimensional echocardiography and arterial tonometry. Am J Physiol Heart Circ Physiol. 2011 Nov; 301(5):H1916-23.
-
McCommis KS, Koktzoglou I, Zhang H, Goldstein TA, Northrup BE, Li D, Gropler RJ, Zheng J. Improvement of hyperemic myocardial oxygen extraction fraction estimation by a diffusion-prepared sequence. Magn Reson Med. 2010 Jun; 63(6):1675-82.
-
Yoshitani H, Takeuchi M, Mor-Avi V, Otsuji Y, Hozumi T, Yoshiyama M. Comparative diagnostic accuracy of multiplane and multislice three-dimensional dobutamine stress echocardiography in the diagnosis of coronary artery disease. J Am Soc Echocardiogr. 2009 May; 22(5):437-42.
-
Donlan SM, Quattromani E, Pang PS, Gheorghiade M. Therapy for acute heart failure syndromes. Curr Cardiol Rep. 2009 May; 11(3):192-201.
-
Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009 Dec; 14(4):277-87.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|